General Information of the Drug (ID: M6APDG03396)
Name
DS-6930
Status
Discontinued in Phase 1
TTD Drug ID
D0Z6OI
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a therapeutic target for DS-6930. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of DS-6930 through regulating the expression of Peroxisome proliferator-activated receptor gamma (PPAR-gamma). [1], [2]
References
Ref 1 The m(6)A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG. Acta Pharmacol Sin. 2022 May;43(5):1311-1323. doi: 10.1038/s41401-021-00756-8. Epub 2021 Aug 30.
Ref 2 Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs. J Pharmacol Sci. 2008 Sep;108(1):40-8. doi: 10.1254/jphs.fp0072346. Epub 2008 Sep 6.